SLC5A2 and type 2 diabetes mellitus: In contrast, observational studies and randomised controlled trials have shown that DKA is uncommon in people with type 2 diabetes treated with SGLT2 inhibitors, with an estimated incidence of 0.6–4.9 events per 1000 patient-years [93].